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ABSTRACT
Objectives: The study was focused on leukoencephalopathies of unknown cause in order to
define a novel, homogeneous phenotype suggestive of a common genetic defect, based on
clinical and MRI findings, and to identify the causal genetic defect shared by patients with this
phenotype.
Methods: Independent next-generation exome-sequencing studies were performed in 2 unrelated
patients with a leukoencephalopathy. MRI findings in these patients were compared with avail-
able MRIs in a database of unclassified leukoencephalopathies; 11 patients with similar MRI
abnormalities were selected. Clinical and MRI findings were investigated.
Results: Next-generation sequencing revealed compound heterozygous mutations in AARS2
encoding mitochondrial alanyl-tRNA synthetase in both patients. Functional studies in yeast con-
firmed the pathogenicity of the mutations in one patient. Sanger sequencing revealed AARS2
mutations in 4 of the 11 selected patients. The 6 patients with AARS2 mutations had childhood-
to adulthood-onset signs of neurologic deterioration consisting of ataxia, spasticity, and cognitive
decline with features of frontal lobe dysfunction. MRIs showed a leukoencephalopathy with strik-
ing involvement of left-right connections, descending tracts, and cerebellar atrophy. All female
patients had ovarian failure. None of the patients had signs of a cardiomyopathy.
Conclusions:Mutations in AARS2 have been found in a severe form of infantile cardiomyopathy in
2 families. We present 6 patients with a new phenotype caused by AARS2 mutations, charac-
terized by leukoencephalopathy and, in female patients, ovarian failure, indicating that the phe-
notypic spectrum associated with AARS2 variants is much wider than previously reported.
Neurology® 2014;82:1–9
GLOSSARY
AARS2 5 alanyl-tRNA synthetase 2; LBSL 5 leukoencephalopathy with brainstem and spinal cord involvement and lactate
elevation; OMIM 5 Online Mendelian Inheritance in Man; tRNA 5 transfer RNA; WES 5 whole-exome sequencing.
Mutations in genes coding for mitochondrial aminoacyl transfer RNA (tRNA) synthetases, the
enzymes that charge a specific tRNA with its cognate amino acid, are recently emerging as a new
important cause of mitochondrial disease and have been associated with a wide spectrum of clin-
ical phenotypes.1–3 However, defects in each aminoacyl tRNA synthetase seem to determine
rather homogeneous clinical presentations.1–5
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The use of whole-exome sequencing (WES)
has markedly increased efficiency and improved
genetic analysis for inherited disorders, allowing
gene identification for small groups of patients
sharing a phenotype, individual cases with atyp-
ical presentation, and disorders lacking consis-
tent genotype-phenotype correlation.6–8
Mutations in the mitochondrial alanyl-
tRNA synthetase 2 gene (AARS2; OMIM
*612035) have been found in severe infantile
cardiomyopathy in 2 families.9 In the present
study, we describe a very different clinical pic-
ture determined by AARS2 genetic defects in 6
patients affected by a progressive leukoenceph-
alopathy and, in females, ovarian failure, a
clinical presentation previously described as
“ovarioleukodystrophy.”10
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved by the Ethical
Committees of the Istituto Neurologico Besta, Milan, Italy; the
Children’s National Medical Center, Washington, DC; and the
VU University Medical Center, Amsterdam, the Netherlands, in
agreement with the Declaration of Helsinki. Informed consent
was signed by the patients.
Patients. Patients 1 (P1) and 2 (P2) were included in 2 indepen-
dent next-generation sequencing studies. On the basis of the MRI
findings in these 2 patients, we selected 10 patients from 9
families from the Amsterdam database, which contains more
than 3,000 cases with an unclassified leukoencephalopathy11
and one patient from the leukoencephalopathy cases of the
Istituto Neurologico Besta without genetic diagnosis. Common
MRI features were frontal and parietal white matter abnormalities
with relative sparing of the central posterior-frontal or
frontoparietal region. The anterior part of the corpus callosum
and a thin strip in the splenium were affected, with relative
sparing of the central region. Most female patients had ovarian
failure in addition to the leukoencephalopathy. We also included
2 patients with unsolved ovarioleukodystrophy, in whom no
mutations in EIF2B1–5 had been found.10,12 For all patients,
we collected clinical and laboratory data retrospectively. We
analyzed available MRIs, as described.10
Molecular studies. We extracted genomic DNA by standard
methods from leukocytes or muscle biopsies. In P1, we performed
WES and variant filtering, as described.13 For P2, we used a cus-
tom probe library for target gene capture (Roche NimbleGen
Inc., Madison, WI) designed to capture coding exons plus 20
base pairs into the flanking introns of 500 genes known to be
related to mitochondrial disorders, followed by deep sequencing
at average coverage depth of 1,000 per base. Because of rapid
clinical deterioration of P2, we also initiated clinical WES (Illu-
mina, San Diego, CA). We performed Sanger sequencing of the
gene identified by WES in all patients.9
Functional studies. We used yeast strains derived from
W303-1B.14 Detailed methods including respiratory activity,
cytochrome spectra, in vivo mitochondrial DNA protein
synthesis, aminoacylation of mitochondrial tRNA for alanine,
cytochrome c oxidase (complex IV) and complex I1 III activities,
and primers for the preparation of plasmids used in this study are
reported in the e-Methods and table e-1 on the Neurology® Web
site at Neurology.org.
RESULTS Patients and laboratory findings. The clini-
cal features of the patients in whom we found muta-
tions in the gene mentioned below are summarized in
table e-2. Herein, we give a brief description.
P1 is a female in whom developmental delay
became evident at 2 years of age. She achieved walk-
ing without support at 3, but with impaired balance.
Her condition remained stable until age 15, when she
developed progressive gait ataxia, tremor, cognitive
deterioration, and psychosis. At age 18, she developed
secondary amenorrhea due to ovarian failure. The lat-
est neurologic examination at age 30 revealed severe
cerebellar ataxia with nystagmus, dysarthria, inten-
tion tremor, and instable gait. She could walk with
support. General physical examination revealed no
abnormalities and no evidence of cardiac dysfunction.
ECG and cardiac ultrasound were normal.
P2 is a male who came to medical attention in
infancy because of congenital nystagmus. In primary
school, mild clumsiness and learning difficulties were
a concern. In his early teenage years, he developed
mild right-sided hemiparesis and ataxia, which was
ascribed to periventricular leukomalacia due to
periventricular white matter abnormalities on MRI.
Around age 17, deterioration set in with bilateral dys-
tonia and spasticity, dysarthria, and cognitive decline.
A viral gastroenteritis was followed by abrupt mental
decline, unintelligible speech, inability to eat due to
choking, recurrent vomiting, and inability to walk
because of worsening of ataxia and spasticity, left
more than right. General physical examination
revealed no abnormalities and no evidence for cardiac
dysfunction.
P3 is a female who presented with secondary amen-
orrhea due to ovarian failure at age 28. At age 33, she
developed depression, cognitive deterioration, behav-
ioral problems with signs of frontal dysfunction, and
urinary incontinence. Neurologic examination re-
vealed downbeat nystagmus and some postural and
appendicular tremor of the arms, but otherwise no
motor disability. She developed stereotyped motor
behavior and severe apraxia. At age 35, she did not rec-
ognize family members anymore. She had to be tube
fed. Antiepileptic medication was started because of
epileptic seizures. At age 36, she was bedridden and
had no interactions with her surroundings.
P4 is a female who was diagnosed with ovarian
failure at age 23 years. She developed tremor of her
hands at age 24. Because of white matter abnormali-
ties on MRI, she was diagnosed with multiple sclero-
sis. From age 26, rapid cognitive, behavioral, and
motor deterioration became evident. She developed
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progressive dystonia, cerebellar ataxia, and spasticity,
left more than right. General physical examination re-
vealed no abnormalities. She lost speech, became bed-
ridden, and died at age 28.
P5 is a female who had primary amenorrhea due to
ovarian failure. From age 40, she developed depres-
sion and rapid cognitive deterioration. Neurologic
examination revealed no motor dysfunction. General
physical examination revealed no abnormalities. She
became bedridden and died at age 46.
P6 is a female who was diagnosed with ovarian
failure at 20 years of age. At age 22, she presented
with gait problems caused by hypertonia of the legs,
left more than right. She developed depression but
no cognitive regression. Neurologic examination re-
vealed a spastic paraparesis with ataxic signs. The dis-
ease was rapidly progressive. At latest examination at
age 25, she was wheelchair-bound.
Laboratory findings are summarized in table e-3.
None of the patients had elevated blood or CSF lac-
tate. All 5 female patients had primary or secondary
amenorrhea due to ovarian failure.
P1 and P6 were the only patients extensively
investigated for a possible mitochondrial defect. In
P1, the Gomori trichrome stain and succinate dehy-
drogenase reaction of a skeletal muscle biopsy were
normal, whereas the histochemical reaction to cyto-
chrome c oxidase was diffusely reduced (figure 1A).
Likewise, biochemical assay showed severe isolated
cytochrome c oxidase deficiency (15% of residual
activity) in muscle homogenate (figure 1B), whereas
the activities of all respiratory chain complexes,
including cytochrome c oxidase, were normal in fi-
broblasts. Oxygraphic studies performed in patients’
fibroblasts, grown in either glucose or galactose
medium, showed no defect (not shown). Sequencing
of mitochondrial DNA revealed a heteroplasmic var-
iant with a low level of mutation load: m.5979G.A
(p.Ala26Thr) in MTCO1, reported as a rare single
nucleotide polymorphism (,0.1% in Mitomap data-
base) present in haplogroup H45 and deemed not
pathogenic. In P6, histologic and histochemical anal-
yses of muscle biopsy revealed diffusely reduced cyto-
chrome c oxidase staining, but no ragged red fibers.
Measurement of individual oxidative phosphoryla-
tion enzyme activities in muscle homogenate showed
reduced cytochrome c oxidase (33% of residual activ-
ity) (figure 1B). Mitochondrial DNA sequencing
revealed no pathogenic point mutations, but several
polymorphisms typical of haplogroup T1a1.
MRI abnormalities. The MRI abnormalities are summa-
rized in table e-4 and illustrated in figures 2 and e-1. In all
6 patients, the cerebral white matter abnormalities were
inhomogeneous and patchy, affecting and sparing strips
of tissue. In several patients, the signal of small parts of
the T2-hyperintense white matter was low on fluid-
attenuated inversion recovery images, indicating white
matter rarefaction. Typically, the signal abnormalities
were predominantly present in the frontal and parietal
periventricular and deep white matter, sparing a segment
of white matter in between.White matter structures were
affected in a tract-like manner, with involvement of left-
right connections through the corpus callosum and
involvement of descending connections. Depending on
the location of the cerebral hemispheric white matter
abnormalities, the frontopontine, pyramidal, or parieto-
occipitopontine tracts were longitudinally affected. The
corpus callosum abnormalities were also dependent on
the cerebral hemispheric white matter involvement; they
could be limited to a single lesion in the splenium, affect
a large part of the anterior corpus callosum and only a
narrow strip in the splenium, or involve the entire corpus
callosum in an inhomogeneous manner. Diffusion-
weighted images showed multiple small areas of
restricted diffusion in the cerebral white matter and
corpus callosum. The abnormalities were limited to
white matter structures and were progressive over time.
No contrast enhancement was observed. Cerebellar
atrophy was variable and affected the vermis more than
the hemispheres. Cerebral atrophy was at most mild.
WES and Sanger sequencing. We performed WES
on genomic DNA from P1.6 After excluding
common single nucleotide polymorphisms (.0.1%),
we prioritized the remaining changes according to the
presence of homozygous or compound heterozygous
mutations, as expected for a recessive inherited trait,
and for known or predicted mitochondrial localization
of the corresponding protein.15 This filtering led to the
identification of a single outstanding gene entry, AARS2
(NC_000006.11), in which a missense (c.149T.G,
p.Phe50Cys) and a nonsense (c.1561C.T, p.Arg521*)
heterozygous variant were present (NM_020745.3)
(figure 1C, table 1), segregating within the family.
We subjected P2 to a gene panel containing 500
genes known to cause mitochondrial disorders and
to clinical WES. With both policies, we identified
2 missense mutations in AARS2 (c.2893G.A,
p.Gly965Arg and c.1213G.A, p.Glu405Lys).
We performed Sanger sequencing of AARS2 exons
and intron-exon boundaries in all patients and found
AARS2 mutations in 4 of the 11 patients selected on
the basis of MRI features (table 1). We did not find
AARS2 mutations in the 2 patients with ovarioleuko-
dystrophy. All identified nucleotide substitutions
with a frequency ,0.01% in public databases corre-
spond to amino acid changes predicted to be delete-
rious (tables 1 and e-5).
Functional studies. Because no biochemical readout was
detected in cell lines of P1, we tested the possible dele-
terious impact of the AARS2 mutations on oxidative
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phosphorylation in a Saccharomyces cerevisiae yeast
model. Phe50 in human AARS2 is highly conserved
in phylogenesis, including yeast (figure e-2), in which
the ortholog ala1 gene (NC_001147.6) codes for
both the cytosolic and mitochondrial alanyl tRNA syn-
thetase.16 We disrupted ala1 by homologous recombi-
nation and re-expressed the wild-type cytosolic isoform
(supplemental data), thus generating a viable
but oxidative phosphorylation–incompetent strain
(ala1L-16X), which lacked the mitochondrial isoform.
In this strain, we expressed either the wild-type ala1
gene (ala1wt), a p.Phe22Cys mutant allele (ala1F22C),
equivalent to the human p.Phe50Cys variant, or a
p.Val500* mutant allele (ala1V500X), equivalent to the
human p.Arg521* variant.
In contrast to ala1wt, the expression of alaV500X
failed to restore growth on nonfermentable sources
(i.e., glycerol). The oxidative growth of the strain
expressing ala1F22C was similar to the wild-type at
28°C but reduced at 37°C (figure e-3). We obtained
similar results from assays evaluating the oxygen con-
sumption (figure 3A), the in vivo mitochondrial pro-
tein synthesis (figure 3B), the activities of the
respiratory chain complexes I 1 III and IV, and the
spectra of mitochondrial respiratory chain cyto-
chromes (figure e-3). Finally, we evaluated the
Figure 1 Biochemical and genetic features
(A) Morphologic analysis of muscle biopsy from patient P1: Gomori trichrome (GT) staining and cytochrome c oxidase (COX)/
succinate dehydrogenase (SDH) histoenzymatic double staining (COX/SDH). Inset shows the reaction in an age-matched
control biopsy. (B) Biochemical activities of mitochondrial respiratory chain complexes in patients P1 and P6 muscle homo-
genates. All enzymatic activities are normalized for citrate synthase activity and indicated as percentages relative to the
mean control value. (C) Genomic structure of AARS2 with exons coding for the aminoacylation (blue) and editing (red)
domains. The arrows indicate the position of mutations identified in this study (black) or previously reported (gray). aThe
2 missense variants p.Arg199Cys and p.Val730Met are on the same allele; the latter (rs35623954) is reported to have a
frequency .1% in control populations, suggesting that the former is the pathogenic variant.
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Figure 2 Brain MRI
(A) MRI in P1 at age 28. The sagittal T1-weighted image shows serious cerebellar atrophy and 2 strips of abnormal signal in the
splenium (arrows in image 1). The axial T2-weighted images show inhomogeneous areas of abnormal signal in the periventricular
white matter. The areas on the left and right are connected signal abnormalities in the corpus callosum (arrows in images 2–4).
(B) MRI in P2 at age 14 (images 1 and 2), age 21 (images 3 and 4), and age 23 (images 5–8). At age 14, a lesion is seen in the
splenium of the corpus callosum (arrow in image 1) and in the right frontal periventricular white matter. The diffusion-weighted
images suggest the presence of multiple small areas of restricted diffusion in the abnormal white matter (arrows in image 3),
confirmed by low signal of the corresponding areas on the apparent diffusion coefficient map (arrows in image 4). The most
recentMRI showsmultiple segments of abnormal signal in the corpus callosum (image 5 and arrows in image 6). More extensive
signal abnormalities are seen in the periventricular white matter, especially on the right (images 6 and 7). Signal abnormalities
extend downward through the posterior limb of the internal capsule and the pyramidal tracts in the brainstem on the right
(arrows in images 7 and 8). (C) MRI in patient 3 at age 35. The midsagittal image shows that the anterior part of the corpus
callosum is abnormal, whereas only a strip of signal abnormality is seen in the splenium (arrows in image 1). Images 2 and 3
illustrate that the frontal andparietal whitematter is abnormal, whereas the central whitematter in between is normal. The tract
involvement is evident (arrows in images 2 and 4). The axial fluid-attenuated inversion recovery image shows that the affected
white matter is rarefied (arrow in image 5). The axial T2-weighted images illustrate the involvement of the anterior limb of the
internal capsule (image 6) and the frontopontine tracts going down into the brainstem (arrows in images 7 and 8).
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charging of the tRNA with alanine; the p.Val500*
change determined the complete inability to charge
mitochondrial tRNAAla with its cognate amino acid,
whereas the p.Phe22Cys change determined a partial
reduction in the amino acid charging at 37°C (figure
3C). We analyzed the effects of ala1L125R, correspond-
ing to p.Leu155Arg,9 and found that in all experi-
ments this missense mutation behaves as a null
allele (figures 3 and e-3). The other known AARS2
mutation, p.Arg592Trp,9 could not be tested, because
the residue is not conserved in yeast (figure e-2).
The above yeast experiments confirmed that the
p.Phe50Cys missense mutation is deleterious only
in stress conditions, whereas the truncated protein
due to the nonsense mutation is nonfunctional.
DISCUSSION Defects in several different mitochon-
drial aminoacyl tRNA synthetases have been associ-
ated with specific clinical phenotypes.1,3–5 However,
these enzymes are ubiquitously expressed and take
part in the same process, so this phenotypic segrega-
tion is difficult to explain. This conclusion of pheno-
typic segregation may be based on inclusion bias,
because the genes are only analyzed in patients with
specific phenotypes. In addition, the number of
patients with mutations in different mitochondrial
aminoacyl tRNA synthetases is at present too small
to provide conclusive evidence of the existence of
exclusive genotype-phenotype correlations.
Recently, AARS2mutations have been reported in
3 subjects as the cause for infantile hypertrophic car-
diomyopathy, lactic acidosis, and brain and skeletal
muscle involvement, with early fatal outcome.9 In
contrast, our patients have later-onset neurologic dys-
function due to a leukoencephalopathy and no signs
of cardiomyopathy. In P1 and P2, onset was in child-
hood and initially followed a stable course or very
slow disease progression. In all cases, the course after
onset of evident deterioration was rather rapid. The
neurologic dysfunction comprised motor deteriora-
tion, consisting of cerebellar ataxia and spasticity,
and cognitive decline with features of frontal lobe
dysfunction with poor memory, inactivity and other
behavioral changes, as well as depression and other
psychiatric features. Comparing clinical and MRI
findings, it is clear that the clinical signs of the patients
depend on which tracts are affected. P2, P4, and P6
had prominent signs of motor dysfunction and had
pyramidal tract involvement on MRI. P3 and P5
mainly had signs of behavioral and cognitive dysfunc-
tion and frontopontine tract involvement. The strik-
ing white matter tract involvement and presence of
spots of restricted diffusion in the cerebral white mat-
ter are features shared by another disorder with muta-
tions in a mitochondrial aminoacyl tRNA synthetase:
“leukoencephalopathy with brainstem and spinal cord
involvement and lactate elevation” (LBSL), caused by
mutations in DARS2 (OMIM *610956). In LBSL,
the white matter spots of restricted diffusion are
ascribed to myelin vacuolization, a feature frequently
seen in mitochondrial leukoencephalopathies.17
In P1 and P6, we detected a profound, isolated
defect of complex IV activity, rather than a combina-
tion of mitochondrial DNA–related respiratory chain
defects, which is the expected consequence of reduced
mitochondrial protein synthesis. The pathogenicity
of the 2 AARS2 variants of P1 was proven in a recom-
binant yeast model. Of note, the yeast p.Phe22Cys
mutation, equivalent to p.Phe50Cys found in P1,
impairs complex IV activity much more than
Table 1 AARS2 mutations found in the patients
Patient cDNA Protein State Paternal/maternal EVS frequency, %a
1 c.149T.G p.Phe50Cys Heterozygous M ø
c.1561C.T p.Arg521* Heterozygous P ø
2 c.2893G.A p.Gly965Arg Heterozygous M ø
c.1213G.A p.Glu405Lys Heterozygous P ø
3 c.1609C.T and c.2350del p.Gln537* and p.Glu784Serfs*9 Heterozygous M ø
c.595C.T and c.2188G.A p.Arg199Cys and p.Val730Met Heterozygous P 0.008 and 3.1
4 c.230C.T p.Ala77Val Heterozygous M 0.008
c.595C.T and c.2188G.A p.Arg199Cys and p.Val730Met Heterozygous P 0.008 and 3.1
5 c.595C.T and c.2188G.A p.Arg199Cys and p.Val730Met Heterozygous M 0.008 and 3.1
c.390_392del p.Phe131del Heterozygous P ø
6 c.595C.T and c.2188G.A p.Arg199Cys and p.Val730Met Heterozygous M 0.008 and 3.1
c.2611dup p.Thr871Asnfs*21 Heterozygous P ø
Abbreviations: cDNA 5 complementary DNA; EVS 5 Exome Variant Server (varianttools.sourceforge.net/Annotation/EVS).
aØ 5 not found.
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complex I1 III activity, whereas p.Leu125Arg, equiv-
alent to human p.Leu155Arg, a mutation of patients
with cardiomyopathy,9 decreases them both, suggesting
that an isolated defect of complex IV may predomi-
nantly depend on specific missense mutations, possibly
influencing the main target tissue (brain vs heart). Var-
iable involvement of different respiratory chain com-
plexes and different degrees of defective activities have
also been reported for different mutations in other ami-
noacyl tRNA synthetases.18
The yeast p.Phe22Cys mutation was only deleteri-
ous in stress conditions, while the other tested muta-
tions were highly deleterious in basal conditions,
suggesting that the human p.Phe50Cys mutant protein
maintains residual activity, which could explain the
slow disease of our patient, in contrast to the rapidly
fatal outcome of the patients with cardiomyopathy.9
While our yeast model enabled us to evaluate the
p.Leu155Arg mutation, poor conservation between
human and yeast precluded the validation of the
p.Arg592Trp substitution in patients with cardiomy-
opathy.9 The latter mutation could impair editing
activity of AARS2, leading to increased mistranslation
of the alanine codon by serine or glycine.9 According to
this hypothesis, a specific pathogenic mechanism, mis-
translation, would lead to cardiomyopathy, while trans-
lation deficiency, caused by other aminoacyl tRNA
synthetase mutations, is usually not associated with
heart damage.3 Of note, hypertrophic cardiomyopathy
occurs in subjects with mutations affecting MTO1,
encoding an enzyme responsible for tRNA modifica-
tions that increase accuracy and efficiency of mitochon-
drial DNA translation.19,20
A striking feature was the presence of ovarian fail-
ure in all female patients with AARS2 mutations.
Mutations in 2 other mitochondrial aminoacyl tRNA
synthetase encoding genes, namely HARS2 (OMIM
*600783) and LARS2 (OMIM *604544), have
recently been associated with Perrault syndrome, a
disorder characterized by ovarian dysgenesis and sen-
sorineural hearing loss. However, Perrault syndrome
is genetically heterogeneous; it can also be caused by
mutations in HSD17B4, encoding a peroxisomal
enzyme involved in fatty acid b-oxidation, and muta-
tions in CLPP, encoding a mitochondrial endopepti-
dase. Mutations in POLG (OMIM *174763), the
gene encoding DNA polymerase-g for the replication
of human mitochondrial DNA, may also lead to pre-
mature menopause21 and ovarian failure.22
Of the 7 patients included in the present study
who had similar MRI abnormalities but no AARS2
mutations, 2 were male and 2 were prepubertal fe-
males. Of the 3 adult female patients, one had normal
menses until put on contraceptive injections, one had
a period of 3 years of amenorrhea but recently started
menstruating again, and for one the information is
Figure 3 Yeast studies
(A) Oxygen consumption rate of the ala1L-16X strain transformed with the ala1wt allele, the
empty vector, and the mutant alleles ala1F22C, ala1V500X, and ala1L125R. Respiratory rates
were normalized to the strain transformed with ala1wt, in which the respiratory rate was
81.1 nmol min21 mg21 at 28°C and 33.4 nmol min21 mg21 at 37°C. Values are the mean of 3
independent experiments, each with an independent clone. Two-tailed paired t test was
applied for statistical significance. ***p , 0.001. (B) In vivo mitochondrial protein synthesis
of the ala1L-16X strain transformed with the ala1wt allele, the empty vector, and the mutant
alleles ala1F22C, ala1V500X, and ala1L125R. Mitochondrial gene products were labeled with
[35S]-methionine in whole cells in the presence of cycloheximide for 10 minutes at 28°C or
37°C. (C) Mitochondrial tRNAAla loading of the ala1L-16X strain transformed with the ala1wt
allele, the empty vector, and the mutant alleles ala1F22C, ala1V500X, and ala1L125R. Signals
were quantified with Quantity 1 (Bio-Rad, Hercules, CA). For each strain, the ratio between
the charged tRNAAla and the uncharged one was calculated and normalized to the ala1wt
strain. Atp 5 ATP synthase; Cob 5 cytochrome b; Cox 5 cytochrome c oxidase; ns 5 not
significant; Var1 5 small mitochondrial ribosome subunit.
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not available. It is therefore not possible to make a
definitive conclusion on the presence or absence of
ovarian failure in these patients.
The preferential involvement of brain white matter
and ovaries is shared by vanishing white matter (OMIM
#603896), caused by mutations in any of the 5 genes
(EIF2B1 to EIF2B5) encoding subunits of the transla-
tion initiation factor eIF2B. Female patients often
develop ovarian failure, manifest as primary or second-
ary amenorrhea.12 eIF2B impairment leads to a defect
in translation initiation for nuclear genes, not affecting
translation of the mitochondrial encoded proteins.
Hence, even if both AARS2 and EIF2B1–5 mutations
are likely associated with block or dysregulation of pro-
tein synthesis, their targets and site of action (mitochon-
dria vs cytosol) are completely separated and, at present,
we have no explanation for the common resulting phe-
notype. Two patients with ovarioleukodystrophy as
well as 7 patients with similar MRI abnormalities had
no AARS2 mutations, suggesting that they have muta-
tions in untranslated regions of the gene or there could
be another gene(s) that, when mutated, is associated
with the same selective vulnerability.
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